

**First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator**

van Kraaij SJW, Gal P, Borghans LGJM, Klaassen ES, Dijkstra F, Winrow C, Glasser C, Groeneveld GJ.

Clinical and translational science

2023; 16(8):1381-1395

**ARTICLE IDENTIFIERS**

DOI: 10.1111/cts.13537

PMID: 37118895

PMCID: PMC10432884

**JOURNAL IDENTIFIERS**

LCCN: 2008247775

pISSN: 1752-8054

eISSN: 1752-8062

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: 101474067

This article was identified from a query of the SafetyLit database.